Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine Hydrochloride, the active ingredient in Orabloc, is a local anesthetic (amide type) presented as a 4% w/v solution for intraoral injection use. It provides local anesthesia for dental procedures and oral surgery in patients requiring pain control.

GNH USA supplies Orabloc as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orabloc (articaine hydrochloride with epinephrine) is employed in dental anesthesia to achieve localized nerve blockade during oral procedures.

- Dental restorative procedures: provides profound anesthesia for fillings, crowns, and bridges. - Endodontic therapy: enables pain‑free root canal treatment. - Oral surgery: facilitates anesthesia for extractions, implant placement, and periodontal surgery.

Adverse reactions may occur following intraoral administration of Orabloc.

Common Side Effects: - Transient lip or cheek numbness. - Mild swelling at the injection site. - Brief metallic taste. - Temporary headache. - Mild dizziness.

Serious or Rare Side Effects: - Allergic reaction, including anaphylaxis. - Prolonged numbness or paresthesia. - Cardiovascular effects from epinephrine (tachycardia, hypertension). - Seizure (rare). - Severe tissue necrosis. - Cardiovascular collapse (extremely rare).

Prior to administration, clinicians should consider several safety measures.

- Assess patient allergy: verify no known hypersensitivity to amide‑type anesthetics or epinephrine. - Evaluate cardiovascular status: avoid use in uncontrolled hypertension or significant cardiac disease. - Use the minimal effective dose: adhere to recommended maximum articaine dose limits. - Caution with MAO inhibitors: epinephrine may precipitate hypertensive crisis. - Pregnancy and lactation: prescribe only if benefit outweighs potential risk. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Artabloc may interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis due to epinephrine. - Beta‑blockers: may mask epinephrine‑induced tachycardia. - Tricyclic antidepressants: potential potentiation of central nervous system toxicity.

Moderate Interactions (Monitor Closely): - Concurrent local anesthetics: cumulative systemic toxicity risk. - Diuretics: may enhance epinephrine‑related cardiac effects. - Anticoagulants: increased bleeding tendency at the injection site.